Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 5
Submit an article Journal homepage
315
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies

Daphne R. FriedmanDepartment of Medicine, Duke University Medical Center, Durham, NC, USACorrespondence[email protected]
,
Mark C. LanasaDepartment of Medicine, Duke University Medical Center, Durham, NC, USA
,
Patricia H. DavisDepartment of Medicine, Duke University Medical Center, Durham, NC, USA
,
Sallie D. AllgoodDepartment of Medicine, Duke University Medical Center, Durham, NC, USA;Durham VA Medical Center, Durham, NC, USA
,
Karen M. MattaDepartment of Medicine, Duke University Medical Center, Durham, NC, USA;Durham VA Medical Center, Durham, NC, USA
,
Danielle M. BranderDepartment of Medicine, Duke University Medical Center, Durham, NC, USA
,
Youwei ChenDepartment of Medicine, Duke University Medical Center, Durham, NC, USA;Durham VA Medical Center, Durham, NC, USA
,
Evan D. DavisDepartment of Medicine, Duke University Medical Center, Durham, NC, USA;Durham VA Medical Center, Durham, NC, USA
,
Alicia D. VolkheimerDepartment of Medicine, Duke University Medical Center, Durham, NC, USA;Durham VA Medical Center, Durham, NC, USA
,
Joseph O. MooreDepartment of Medicine, Duke University Medical Center, Durham, NC, USA
,
Jon P. GockermanDepartment of Medicine, Duke University Medical Center, Durham, NC, USA
,
Peter SportelliKeryx Biopharmaceuticals, New York, NY, USA
&
J. Brice WeinbergDepartment of Medicine, Duke University Medical Center, Durham, NC, USA;Durham VA Medical Center, Durham, NC, USA
 show all
Pages 1067-1075 | Received 23 Apr 2013, Accepted 05 Jul 2013, Published online: 31 Aug 2013

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Hany Khalil, Amira Abd ElHady, Khaled A. Elawdan, Dalia Mohamed, Doaa D. Mohamed, Ahmed I Abd El Maksoud, Farha A. El-Chennawi, Bhgat El-Fikiy & Ibrahim H. El-Sayed. (2022) The Mechanical Autophagy as a Part of Cellular Immunity; Facts and Features in Treating the Medical Disorders. Immunological Investigations 51:2, pages 266-289.
Read now
Agata M. Bogusz & Adam Bagg. (2016) Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets. Leukemia & Lymphoma 57:9, pages 1991-2013.
Read now

Articles from other publishers (17)

Maha M. Salama, Nora M. Aborehab, Nihal M. El Mahdy, Ahmed Zayed & Shahira M. Ezzat. (2023) Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials. European Journal of Medical Research 28:1.
Crossref
Clemens Holz, Sandra Lange, Anett Sekora, Gudrun Knuebel, Saskia Krohn, Hugo Murua Escobar, Christian Junghanss & Anna Richter. (2023) Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells. International Journal of Molecular Sciences 24:2, pages 1359.
Crossref
Faustino Mollinedo & Consuelo Gajate. (2021) Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer. Cancers 13:16, pages 4173.
Crossref
Xiaowei Zhang & Yuanbo Liu. (2020) Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects. CNS & Neurological Disorders - Drug Targets 19:3, pages 165-173.
Crossref
Nicola Relitti, Akella P. Saraswati, Stefano Federico, Tuhina Khan, Margherita Brindisi, Daniela Zisterer, Simone Brogi, Sandra Gemma, Stefania Butini & Giuseppe Campiani. (2020) Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. Current Topics in Medicinal Chemistry 20:6, pages 433-457.
Crossref
Tao Lei, Yongwei Hong, Xinyue Chang, Zhimin Zhang, Xingguo Liu, Miao Hu, Wenhai Huang & Haiyan Yang. (2020) Discovery of the Potent Phosphoinositide 3‐Kinase δ (PI3 K δ) Inhibitors. ChemistrySelect 5:1, pages 196-200.
Crossref
Ferda Kaleağasıoğlu, Maya M. Zaharieva, Spiro M. Konstantinov & Martin R. Berger. (2019) Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy. Anti-Cancer Agents in Medicinal Chemistry 19:1, pages 66-91.
Crossref
Oren J. Becher, Nathan E. Millard, Shakeel Modak, Brian H. Kushner, Sofia Haque, Ivan Spasojevic, Tanya M. Trippett, Stephen W. Gilheeney, Yasmin Khakoo, David C. Lyden, Kevin C. De Braganca, Jill M. Kolesar, Jason T. Huse, Kim Kramer, Nai-Kong V. Cheung & Ira J. Dunkel. (2017) A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PLOS ONE 12:6, pages e0178593.
Crossref
Bethany A. Kerr, Xiaoxia Z. West, Young-Woong Kim, Yongzhong Zhao, Miroslava Tischenko, Rebecca M. Cull, Timothy W. Phares, Xiao-Ding Peng, Jeremiah Bernier-Latmani, Tatiana V. Petrova, Ralf H. Adams, Nissim Hay, Sathyamangla V. Naga Prasad & Tatiana V. Byzova. (2016) Stability and function of adult vasculature is sustained by Akt/Jagged1 signalling axis in endothelium. Nature Communications 7:1.
Crossref
Charles B Goodwin & Rebecca J. Chan. 2016. PI3K-mTOR in Cancer and Cancer Therapy. PI3K-mTOR in Cancer and Cancer Therapy 181 229 .
Lars Fransecky, Liliana H Mochmann & Claudia D Baldus. (2015) Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Molecular and Cellular Therapies 3:1.
Crossref
Robert N. Mahon & Richard Hafner. (2015) Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis : An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases . Clinical Infectious Diseases 61:suppl 3, pages S200-S216.
Crossref
Brody Holohan, Moriah M. Hagiopian, Tsung-Po Lai, Ejun Huang, Daphne R. Friedman, Woodring E. Wright & Jerry W. Shay. (2015) Perifosine as a potential novel anti-telomerase therapy. Oncotarget 6:26, pages 21816-21826.
Crossref
Michael Murray, Adam Hraiki, Mary Bebawy, Curtis Pazderka & Tristan Rawling. (2015) Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs. Pharmacology & Therapeutics 150, pages 109-128.
Crossref
Hui Jun Lim, Philip Crowe & Jia-Lin Yang. (2014) Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. Journal of Cancer Research and Clinical Oncology 141:4, pages 671-689.
Crossref
Alice Cani, Carolina Simioni, Alberto M. Martelli, Giorgio Zauli, Giovanna Tabellini, Simona Ultimo, James A. McCubrey, Silvano Capitani & Luca M. Neri. (2015) Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget 6:9, pages 6597-6610.
Crossref
Agata Majchrzak, Magdalena Witkowska & Piotr Smolewski. (2014) Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance. Molecules 19:9, pages 14304-14315.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.